| Date | Title | | | December 11, 2014 | LifeMap Sciences, a Subsidiary of BioTime, Announces Release of MalaCards Version 1.07 with additional types of clinical significance from ClinVar and new phenotypes from HPO| ALAMEDA, Calif., December 11, 2014 – LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the release of MalaCards, Version 1.07. The new release is available at http://www.malacards.org/. MalaCards is a database of human diseases and their annotations that is modeled on the architecture and richness of the popular GeneCards® database of human genes (http://www.genecards.org/). The database consolidates disease data from 65 sources and in this version contains 19,811 dis... |
|  | | November 18, 2014 | Asterias Biotherapeutics Named as a "Top Advanced Therapies Projects to Watch" and Will Present at the Therapeutic Area Partnerships Conference| MENLO PARK, Calif., Nov. 18, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that the Company's lead clinical program, AST-OPC1 (oligodendrocyte progenitor cells) for complete cervical spinal cord injury (SCI), has been selected as one of ten "Top Advanced Therapies Projects to Watch" by Elsevier Business Intelligence.
"We are delighted to receive this significant industry hono... |
| | | November 17, 2014 | Asterias Biotherapeutics to Participate in Live Google Hangout Discussion of Stem Cell-Based Therapies for Spinal Cord Injury| MENLO PARK, Calif., Nov. 17, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Jane S. Lebkowski, Ph.D., Asterias' President of Research and Development, will participate in a live Google Hangout session presented by the California Institute for Regenerative Medicine (CIRM) discussing the latest progress in stem cell-based therapies for spinal cord injury (SCI).
The CIRM Goo... |
| | | November 10, 2014 | Asterias Biotherapeutics Reports Third Quarter Financial and Operating Results| MENLO PARK, Calif., Nov. 10, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2014.
"Asterias made substantial progress in the third quarter with respect to our two key development programs that have the potential to address significant unmet medical needs using our pluripotent stem cell technology platfo... |
| | | November 03, 2014 | BioTime’s Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa Trial of Embryonic Stem Cell-Derived OpRegen® for the Treatment of the Dry Form of Age-Related Macular Degeneration| IND cleared for Phase I/IIa dose escalation trial in patients with
the dry form of age-related macular degeneration (AMD) called
geographic atrophy (GA)
No approved therapy exists for dry-AMD, the leading cause of visual
impairment in an aging population in the US and other developed
countries
OpRegen® will
be the first preparation of xeno-free human embryonic stem
cell-derived RPE cells evalu... |
| | | October 31, 2014 | Asterias Biotherapeutics to Report Third Quarter Results on November 10, 2014| MENLO PARK, Calif., Oct. 31, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it will release third quarter financial and operating results on Monday, November 10, 2014 after the close of the U.S. financial markets. The Company will host a conference call via webcast on Monday, November 10, 2014 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss third quarter results and rece... |
| | | October 20, 2014 | Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury| Provides for Immediate Release of Initial Grant Funds
Menlo Park, Calif., October 20, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST) announced today that the Company has signed a Notice of Grant Award (NGA) with the California Institute of Regenerative Medicine (CIRM), effective October 1, 2014. The NGA provides for the immediate release of Clinical Development payments and the release of additional grant funds pursuant to the previously announced $14.3 million CI... |
| | | October 06, 2014 | Asterias Biotherapeutics to List its Series A Common Stock on NYSE MKT| Trading on NYSE MKT Expected to Begin on October 8, 2014 under Ticker Symbol AST
MENLO PARK, Calif., Oct. 6, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (OTCBB: ASTY) announced today that it received approval to list its Series A common stock on the NYSE MKT under the ticker symbol "AST." The Company's shares are expected to begin trading on the NYSE MKT on October 8, 2014. Prior to that date, the Company's Series A common stock will continue to trade on the OTC Bulletin Board (OTCBB)... |
| | | October 06, 2014 | BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Files an IND with the FDA for OpRegen® Designed to Treat Patients with Dry-AMD| IND filed for a Phase I/IIa dose escalation trial in patients with
dry-AMD
No approved therapy exists for dry-AMD, the leading cause of visual
impairment in the aging population
OpRegen® will
be the first preparation of xeno-free RPE cells to be evaluated
clinically for dry-AMD
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Oct. 6, 2014--
BioTime, Inc. (NYSE MKT: BTX), HBL Hadasit B... |
| | | October 06, 2014 | LifeMap Sciences, a Subsidiary of BioTime, Announces Release of MalaCards Version 1.06 with greatly improved gene-disease associations| ALAMEDA, Calif., October 6, 2014 – LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the recent release of MalaCards, Version 1.06. The new release is available at http://www.malacards.org/, and features greatly improved gene-disease associations. MalaCards is a database of human diseases and their annotations that is modeled on the architecture and richness of the popular GeneCards® database of human genes (http://www.genecards.org/). The database consolidates disease... |
| | | October 06, 2014 | LifeMap Sciences Announces Release and Commercial Availability of GeneAnalytics™ 1.0, a Powerful Gene Set Analysis Tool powered by GeneCards®, LifeMap Discovery® and MalaCards| ALAMEDA, Calif., October 6, 2014 – LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the commercial release of GeneAnalytics 1.0 atwww.geneanalytics.com. GeneAnalytics™ is a powerful, yet easy to use, gene set analysis tool designed to help life scientists and biomedical researchers identify expression signatures and functionality of their experimental gene sets, and define their roles in various biological processes and in health and disease.
GeneAnalytics™ is power... |
| | | October 01, 2014 | LifeMap Solutions Adds Chief Technology Officer to Leadership Team| Additional Experts from Partner Icahn Institute at Mount Sinai Form
Science Team
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 1, 2014--
BioTime, Inc. (NYSE MKT:BTX) and its subsidiary LifeMap Solutions, Inc.,
a medical technology company, today announced significant additions to
the LifeMap Solutions management team. LifeMap Solutions is partnering
with the Icahn Institute at Mount Sinai to create innovative mobile
health (mHealth) products and serv... |
| | | September 29, 2014 | Asterias Biotherapeutics Announces Distribution Date of BioTime Warrants and Conversion Date of Series B Common Stock into Series A Common Stock| Applies for Listing on the NYSE MKT
MENLO PARK, Calif.--(BUSINESS WIRE)--Sep. 29, 2014--
Asterias Biotherapeutics, Inc. (OTCBB: ASTY) announced today that on
October 1, 2014 the company will distribute 8,000,000 warrants to
purchase common shares of BioTime, Inc. (the “BioTime Warrants”) at a
purchase price of $5.00 per common share to holders of record on
September 15, 2014 of its Series A common stock. Asterias Series A
common stock will tra... |
| | | September 19, 2014 | BioTime, Inc.’s Subsidiary OncoCyte Corporation’s CEO Dr. Joseph Wagner to Present at BTIG’s Inaugural “Emerging Technologies in Healthcare Diagnostics” Symposium| ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 19, 2014--
OncoCyte Corporation, a subsidiary of BioTime, Inc. (NYSE MKT: BTX),
today announced that Chief Executive Officer Joseph Wagner, Ph.D. is
scheduled to present at the inaugural BTIG Emerging Technologies in
Healthcare Diagnostics Symposium being held September 29-30, 2014 at The
Benjamin Hotel in New York City. As part of the symposium, leading
diagnostic companies will present on a series of thematic pane... |
| | | September 17, 2014 | BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Demonstrates the Safety and Efficacy of OpRegen® in Preclinical Animal Studies| ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Sep. 17, 2014--
BioTime, Inc. (NYSE MKT: BTX), HBL Hadasit Bio-Holdings Ltd. (Tel Aviv
Stock Exchange: HDST) and Cell Cure Neurosciences Ltd. (Cell Cure) today
announced that Cell Cure has received the final results of a series of
extensive preclinical safety and efficacy studies of its
development-stage product designated OpRegen®,
which is intended for use in the treatment of dry form age-related
... |
| | | September 15, 2014 | BioTime, Inc.’s Subsidiary OncoCyte Corporation and Abcodia to Collaborate on Breast Cancer Diagnostic Development| PanC-Dx™ Markers to be Validated Using
Pre-Diagnosis Patient Serum Samples Exclusively Provided by Abcodia
ALAMEDA, Calif. & LONDON--(BUSINESS WIRE)--Sep. 15, 2014--
OncoCyte Corporation, a subsidiary of BioTime, Inc. (NYSE MKT: BTX), and
Abcodia Ltd., a UK-based company focusing on the early detection of
cancer, today announced their collaboration focused on the development
of OncoCyte’s blood-based PanC-Dx™ test for early detection of
br... |
| | | September 11, 2014 | BioTime Subsidiary, Asterias Biotherapeutics, and Cancer Research UK and Cancer Research Technology Partner for Clinical Trial of Immunotherapy Vaccine for Lung Cancer| ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 11, 2014--
BioTime, Inc. (NYSE MKT: BTX) announced that its subsidiary Asterias
Biotherapeutics, Inc. (OTCBB: ASTY) has reached an agreement with Cancer
Research UK and Cancer Research Technology (CRT), the charity’s
development and commercialization arm, to conduct a clinical
trial of Asterias’ novel immunotherapy treatment AST-VAC2 in subjects
with non-small cell lung cancer.
AST-VAC2 is a non-patie... |
| | | September 11, 2014 | Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer| -Conference Call and Webcast on September 12, 2014 at 8:30 a.m. ET, 5:30 a.m. PT-
MENLO PARK, Calif. and LONDON, Sept. 11, 2014 /PRNewswire/ -- CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subje... |
| | | September 04, 2014 | Asterias Biotherapeutics Announces Record Date for Distribution of BioTime Warrants to Holders of Asterias Series A Common Stock| MENLO PARK, Calif., Sept. 4, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (OTCBB: ASTY) announced today that its Board of Directors has set Monday, September 15, 2014 as the record date (the "Record Date") for determining holders of its Series A common stock entitled to receive BioTime, Inc. common share purchase warrants in Asterias' previously announced warrant distribution.
Asterias plans to distribute, on a pro rata basis, warrants to purchase 8,000,000 BioTime common shares at an ... |
| | | August 27, 2014 | BioTime Subsidiary Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients With Cervical Complete Spinal Cord Injury| Dose Escalation Clinical Trial to Test Initial Safety and Activity of
AST-OPC1 in Patient Population with the First Indication Targeted for
Product Registration
FDA Clearance Triggers Definitive Contract Finalization with
California Institute of Regenerative Medicine (CIRM) to Begin $14.3
Million in Trial Funding
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 27, 2014--
BioTime, Inc. (NYSE MKT:BTX) announced that its subsidiary Asterias
... |
| | | August 27, 2014 | Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury| Dose Escalation Clinical Trial to Test Initial Safety and Activity of AST-OPC1 in Patient Population with the First Indication Targeted for Product Registration
FDA Clearance Triggers Definitive Contract Finalization with California Institute of Regenerative Medicine (CIRM) to Begin $14.3 Million in Trial Funding
MENLO PARK, Calif., Aug. 27, 2014 /PRNewswire/ -- Asterias Biotherapeutics Inc. (OTCBB: ASTY) has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a... |
| | | August 25, 2014 | Asterias Biotherapeutics Announces Investor Briefing Conference Call and Webcast| - Wednesday, August 27, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT -
MENLO PARK, Calif., Aug. 25, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it will host an investor briefing conference call and slide presentation via webcast on Wednesday, August 27, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT. At this briefing, Asterias management will review the Company's business strategy and ... |
| | | August 21, 2014 | Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution| Welcomes New Shareholders Who Received Series A Shares from Geron Corporation
Menlo Park, Calif., August 21, 2014 -- Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today the appointments of Andrew ("Andy") Arno and Natale ("Nat") Ricciardi to the Company's newly expanded Board of Directors. With these additions, the Asterias Board of Directors now comprises eight directors, three of whom are indep... |
| | | July 31, 2014 | BioTime, Inc. Subsidiary OncoCyte Corporation Expands Clinical Development of Bladder Cancer Diagnostic by Initiating a Large Multi-Site Clinical Trial| - PanC-Dx™ Markers to be Tested on Over 1,000
Patient Samples from Urology Clinics Located Throughout United States-
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 31, 2014--
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation
today announced that OncoCyte has expanded the clinical development of
its urine-based bladder cancer diagnostic test by initiating a
multi-site clinical trial. The trial, which will involve up to 1,20... |
| | | July 24, 2014 | Asterias Biotherapeutics Announces Live Investor Webcast| - Tuesday, July 29, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT -
Menlo Park, Calif., July 24, 2014 -- Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it will host a live webcast of a presentation to investors on Tuesday, July 29, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT. The presentation will include an overview of Asterias’ business strategy and product development pipeline. To access the webcast, visit... |
| | | July 10, 2014 | LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards® Version 3.12 and the Introduction of GeneCards Plus™| New release features powerful tools for registered members
ALAMEDA, Calif., July 10, 2014 – LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the release of GeneCards® Version 3.12. The new release is available at www.genecards.org. GeneCards® is an online database that provides comprehensive information on all known human genes. The new release features the launc... |
| | | June 17, 2014 | BioTime Subsidiary Asterias Biotherapeutics Raises $13.0 Million in Equity Financing| Capital infusion provides funding to advance Asterias’ therapeutic
programs
Substantially strengthens Asterias’ cash position
ALAMEDA, Calif. & MENLO PARK, Calif.--(BUSINESS WIRE)--Jun. 17, 2014--
BioTime,
Inc. (NYSE MKT: BTX) announced today that its subsidiary Asterias
Biotherapeutics, Inc. (“Asterias”), has raised $12.5 million through
the sale of 5,000,000 BioTime common shares held by Asterias and the
... |
| | | June 17, 2014 | BioTime Subsidiary Asterias Biotherapeutics Announces Investment by CEO| CEO Pedro Lichtinger purchases 200,000 shares of Asterias Series B
common stock
ALAMEDA, Calif. & MENLO PARK, Calif.--(BUSINESS WIRE)--Jun. 17, 2014--
BioTime,
Inc. (NYSE MKT: BTX) today announced that on June 12, 2014, Pedro
Lichtinger, President and Chief Executive Officer of its subsidiary Asterias
Biotherapeutics, Inc. (“Asterias”) purchased from Asterias 200,000
shares of Asterias Series B common stock at a price of $2.34 pe... |
| | | June 12, 2014 | BioTime Subsidiary Asterias Biotherapeutics Appoints Former Pfizer Senior Executive Pedro Lichtinger as President and Chief Executive Officer| Pharmaceutical and Biotechnology Industry Professional with 35
Years of Experience
Extensive Track Record of Successful Drug Development and
Commercialization
Focused on Advancing Lead Product Candidates in Neurology and
Cancer
Immunotherapy
ALAMEDA, Calif. & MENLO PARK, Calif.--(BUSINESS WIRE)--Jun. 12, 2014--
BioTime, Inc. (NYSE MKT: BTX) today announced that Pedro Lichtinger has
... |
| | | May 30, 2014 | BioTime's Subsidiary Asterias Biotherapeutics, Inc. Announces a $14.3 Million Strategic Partnership Award from the California Institute for Regenerative Medicine| Award Supports Phase 1/2a Dose Escalation Clinical Trial of
AST-OPC1 in Cervical Spinal Cord Injury
Funding Provides for the Expansion of AST-OPC1 Clinical Trial
Originally Initiated by Geron Corporation into Target Population for
Pivotal Studies
MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--May 30, 2014--
Asterias Biotherapeutics, Inc. (“Asterias”), a subsidiary of BioTime,
Inc. (NYSE MKT: BTX), to... |
| | | May 28, 2014 | BioTime’s Subsidiary Asterias Biotherapeutics, Inc. Settles Patent Interference Proceedings| MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--May 28, 2014--
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Asterias
Biotherapeutics, Inc. (“Asterias”), announced that Asterias has entered
into a settlement agreement with ViaCyte, Inc. (“ViaCyte”) concerning
certain litigation in the United States District Court for the Northern
District of California (Civil Action No. C12-04813) seeking the reversal
of two adverse determinations by the Un... |
| | | May 27, 2014 | BioTime’s Subsidiary OncoCyte Corporation and Cornell University Enter License Agreement to Accelerate Lung Cancer Diagnostic Product Development| - PanC-Dx™ Markers to be Tested in Patient
Samples Collected by Investigators at Weill-Cornell Medical Center -
ALAMEDA, Calif.--(BUSINESS WIRE)--May 27, 2014--
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation
today announced that OncoCyte has entered into a License Agreement with
Cornell University through which Weill Cornell Medical College will
provide blood samples derived from healthy people and lung cancer
patients f... |
| | | May 22, 2014 | Asterias Biotherapeutics, Inc. Announces New Results from First-in-Man Clinical Trial of a Cell Therapy Derived from Embryonic Stem Cells| - No Serious Adverse Events Related to AST‑OPC1 Administration Reported in Phase 1 Trial of AST-OPC1, Originally Initiated by Geron Corporation, in Patients with Spinal Cord Injury
- No Evidence of Antibody-Based or Cellular Immune Responses
Menlo Park, Calif., May 22, 2014 -- Asterias Biotherapeutics (“Asterias”) presented today the results of its Phase 1 clinical trial assessing the safety of its product, AST-OPC1, in subjects with spinal cord injury. The results were presented by Dr. Jane L... |
| | | May 21, 2014 | Asterias Biotherapeutics, Inc. Launches New Website: Asteriasbiotherapeutics.com| BioTime, Inc. Subsidiary Acquired Geron Corp’s Therapeutic Stem Cell
Assets in Oct. 2013
MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--May 21, 2014--
Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE MKT:
BTX) that is developing clinical-stage stem cell therapeutic assets
acquired from Geron Corporation, today announced the launch of its new
website, www.asteriasbiotherapeutics.com.
The website provides informati... |
| | | May 13, 2014 | Asterias Biotherapeutics, Inc. to Present Phase I Clinical Data at the 17th Annual Meeting of the American Society of Gene & Cell Therapy| ALAMEDA, Calif.--(BUSINESS WIRE)--May 13, 2014--
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Asterias
Biotherapeutics, Inc. today announced that Jane S. Lebkowski, PhD,
President, Research & Development of Asterias, will present at the 17th
Annual Meeting of the American Society of Gene & Cell Therapy
taking place May 20-24, 2014 in Washington, DC.
Dr. Lebkowski’s presentation will take place in the session titled The
Next Gen... |
| | | May 07, 2014 | LifeMap Solutions, Inc. to Develop Mobile Health Products With Mount Sinai’s Icahn School of Medicine| ALAMEDA, Calif.--(BUSINESS WIRE)--May 7, 2014--
BioTime, Inc. (NYSE MKT:BTX) announced today that its subsidiary LifeMap
Sciences, Inc., a technology leader in online biomedical information,
has created LifeMap Solutions, Inc., a medical technology startup
focused on creating innovative mobile health (mHealth) products and
services powered by biomedical and other personal big data. The initial
planned product is envisioned to provide information based on... |
| | | March 13, 2014 | LifeMap Sciences Announces Release of LifeMap Discovery® Version 1.6 with Tissue-Specific, Fully Annotated Summaries of Gene Expression | ALAMEDA, Calif., March 13, 2014 – LifeMap Sciences, Inc. announced today the release of LifeMap Discovery® version 1.6 (discovery.lifemapsc.com). LifeMap Discovery® is a state-of-the-art roadmap of embryonic development and stem cell biology. The product integrates embryonic development and stem cell biology, molecular, cellular, anatomical, and disease-related information, and provides data-mining capabilities and bioinformatics applications. As such, it is a unique and powerful tool for resear... |
| | | March 10, 2014 | LifeMap Sciences Announces Release of MalaCards Version 1.05 with New Categorization| ALAMEDA, Calif., March 10, 2014 – LifeMap Sciences, Inc. announced today the release of MalaCards, Version 1.05. The new release is available at www.malacards.org. MalaCards is a database of human diseases and their annotations that is modeled on the architecture and richness of the popular GeneCards® database of human genes (www.genecards.org). The database consolidates disease data from 61 sources and in this version contains 19,392 disease entries, 11,915 of which include associated genes. Li... |
| | | January 27, 2014 | BioTime, Inc. Subsidiary OncoCyte Corporation Initiates Clinical Development of Bladder Cancer Diagnostics in the United States and China| - PanC-Dx™ Markers to be Tested Include Those
Recently Awarded Patent Protection -
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 27, 2014--
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation
today announced that OncoCyte has initiated clinical development of its
bladder cancer diagnostic test in both the United States and China. In
the United States, OncoCyte has entered into a Clinical Trial Agreement
with a leading medical instit... |
| | | January 17, 2014 | BioTime’s Subsidiary LifeMap Sciences Announces Release of LifeMap Discovery™ Version 1.5 with GeneAnalytics™, a Powerful Gene Expression Analysis Tool| ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 17, 2014--
LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX),
announced today the release of LifeMap Discovery™ version 1.5 (discovery.lifemapsc.com).
LifeMap Discovery™ is a state-of-the-art roadmap of embryonic
development and stem cell biology. The product integrates embryonic
development and stem cell biology, molecular, cellular, anatomical, and
disease-related information, and provides data... |
| | | January 02, 2014 | Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Leases Facilities for Expanded Product Development and Manufacturing| MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 2, 2014--
Asterias Biotherapeutics, Inc. and BioTime, Inc. (NYSE MKT: BTX) today
announced that Asterias has executed a long term lease for a research,
development and manufacturing facility to house all of its cell therapy
product development activities. Located at 6300 Dumbarton Circle,
Fremont, California, the leased facility contains approximately 44,000
square feet of existing office, l... |
| |
|
